Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

TMO Licenses Integrated Genomics’ Software to Advance its Bioethanol Program

  • TMO Renewables gained access to Integrated Genomics’ ERGO™ bioinformatics software that will aid in itsbioethanol production research. 

    “We believe we have developed uniquely talented high-temperature process organisms capable of producing bioethanol quickly and efficiently from a wide diversity of sustainable cellulosic feedstocks,” says Steven Martin, Ph.D., associate R&D director at TMO. “The ERGO platform will enable us to further understand and exploit our thermophilic strains to their fullest potential to deliver the next generation of green biofuels.”

    TMO will utilize the ERGO genome analysis tools for gene annotation, metabolic reconstruction, enzyme data-mining, as well as comparative genomics. The tecnology integrates biological data from genomics, biochemistry, gene-expression studies, genetics, and literature. The platform combines pattern-based analyses with comparative genomics tools for gene visualization in the contexts of regulation, expression data, phylogeny, chromosomal neighborhoods, and gene fusions. ERGO contains more than 1,180 genomes at various stages of completion as well as the largest available collection of networked cellular pathways, according to the TMO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »